Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lenzilumab & Evusheld Make It Onto EU List Of ‘Most Promising’ COVID-19 Treatments

EMA Begins Rolling Review Of Molnupiravir

Executive Summary

Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.

You may also be interested in...



Pfizer And MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid

An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it necessarily represents a good deal for lower-income countries.

Pfizer & MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid

An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it’s necessarily a good deal for lower-income countries.

EMA Considers EUA-Style Fast Track Decision For Molnupiravir

The European Medicines Agency is considering making a rapid recommendation on MSD’s molnupiravir in order to speed access to the potential ‘game changer’ COVID-19 pill.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145146

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel